StreetInsider
Log in to your account:
Log in
Signup
Home
EPS Insider
Event Calendar
Conferences
Classic Site
Upgrade to SI Premium - Free Trial
H.C. Wainwright Reiterates Neutral Rating on BioMarin Pharmaceutical Inc. (BMRN)
July 14, 2026 6:57 AM
H.C. Wainwright analyst Mitchell Kapoor reiterated a Neutral rating and $50.00 price target on BioMarin Pharmaceutical Inc. (NASDAQ: BMRN).The analyst ...
(Premium-only article. Please sign in or upgrade to SI Premium to view.)
Categories
Analyst Comments
